These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

65 related articles for article (PubMed ID: 18507025)

  • 21. PKC412 (CGP41251) modulates the proliferation and lipopolysaccharide-induced inflammatory responses of RAW 264.7 macrophages.
    Miyatake K; Inoue H; Hashimoto K; Takaku H; Takata Y; Nakano S; Yasui N; Itakura M
    Biochem Biophys Res Commun; 2007 Aug; 360(1):115-21. PubMed ID: 17585881
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Divergent cytotoxic effects of PKC412 in combination with conventional antileukemic agents in FLT3 mutation-positive versus -negative leukemia cell lines.
    Furukawa Y; Vu HA; Akutsu M; Odgerel T; Izumi T; Tsunoda S; Matsuo Y; Kirito K; Sato Y; Mano H; Kano Y
    Leukemia; 2007 May; 21(5):1005-14. PubMed ID: 17330105
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Protein kinase C regulation of corneal endothelial cell proliferation and cell cycle.
    Graham MA; Rawe I; Dartt DA; Joyce NC
    Invest Ophthalmol Vis Sci; 2000 Dec; 41(13):4124-32. PubMed ID: 11095605
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [nm23-H1 gene inhibits lung cancer cell invasion through down-regulation of PKC signal pathway].
    Nie Q; Zhou QH; Zhu W; Liu LX; Fu JK; Li DB; Li Y; Che GW
    Zhonghua Zhong Liu Za Zhi; 2006 May; 28(5):334-6. PubMed ID: 17044994
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A novel treatment approach for low grade lymphoproliferative disorders using PKC412 (CGP41251), an inhibitor of protein kinase C.
    Virchis A; Ganeshaguru K; Hart S; Jones D; Fletcher L; Wright F; Wickremasinghe R; Man A; Csermak K; Meyer T; Fabbro D; Champain K; Yap A; Prentice HG; Mehta A
    Hematol J; 2002; 3(3):131-6. PubMed ID: 12111648
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The FLT3 inhibitor PKC412 in combination with cytostatic drugs in vitro in acute myeloid leukemia.
    Möllgård L; Deneberg S; Nahi H; Bengtzen S; Jonsson-Videsäter K; Fioretos T; Andersson A; Paul C; Lehmann S
    Cancer Chemother Pharmacol; 2008 Aug; 62(3):439-48. PubMed ID: 17960382
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heregulin-induced apoptosis is mediated by down-regulation of Bcl-2 and activation of caspase-7 and is potentiated by impairment of protein kinase C alpha activity.
    Le XF; Marcelli M; McWatters A; Nan B; Mills GB; O'Brian CA; Bast RC
    Oncogene; 2001 Dec; 20(57):8258-69. PubMed ID: 11781840
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Superior activity of the combination of histone deacetylase inhibitor LAQ824 and the FLT-3 kinase inhibitor PKC412 against human acute myelogenous leukemia cells with mutant FLT-3.
    Bali P; George P; Cohen P; Tao J; Guo F; Sigua C; Vishvanath A; Scuto A; Annavarapu S; Fiskus W; Moscinski L; Atadja P; Bhalla K
    Clin Cancer Res; 2004 Aug; 10(15):4991-7. PubMed ID: 15297399
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Signal transducer and activator of transcription 3 is involved in cell growth and survival of human rhabdomyosarcoma and osteosarcoma cells.
    Chen CL; Loy A; Cen L; Chan C; Hsieh FC; Cheng G; Wu B; Qualman SJ; Kunisada K; Yamauchi-Takihara K; Lin J
    BMC Cancer; 2007 Jun; 7():111. PubMed ID: 17598902
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FGFR3 as a therapeutic target of the small molecule inhibitor PKC412 in hematopoietic malignancies.
    Chen J; Lee BH; Williams IR; Kutok JL; Mitsiades CS; Duclos N; Cohen S; Adelsperger J; Okabe R; Coburn A; Moore S; Huntly BJ; Fabbro D; Anderson KC; Griffin JD; Gilliland DG
    Oncogene; 2005 Dec; 24(56):8259-67. PubMed ID: 16091734
    [TBL] [Abstract][Full Text] [Related]  

  • 31. UCN-01 (7-hydroxystaurosporine) induces apoptosis and G1 arrest of both primary and metastatic oral cancer cell lines in vitro.
    Otsubo A; Bhawal UK; Nomura Y; Mitani Y; Ozawa K; Kuniyasu H; Sugiyama M
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Mar; 103(3):391-7. PubMed ID: 17321452
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DNA repair contributes to the drug-resistant phenotype of primary acute myeloid leukaemia cells with FLT3 internal tandem duplications and is reversed by the FLT3 inhibitor PKC412.
    Seedhouse CH; Hunter HM; Lloyd-Lewis B; Massip AM; Pallis M; Carter GI; Grundy M; Shang S; Russell NH
    Leukemia; 2006 Dec; 20(12):2130-6. PubMed ID: 17066094
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protein kinase C is inhibited by bisphosphonates in prostate cancer PC-3 cells.
    Tatsuda Y; Iguchi K; Usui S; Suzui M; Hirano K
    Eur J Pharmacol; 2010 Feb; 627(1-3):348-53. PubMed ID: 19903468
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel derivative of doxorubicin, AD198, inhibits canine transitional cell carcinoma and osteosarcoma cells in vitro.
    Rathore K; Cekanova M
    Drug Des Devel Ther; 2015; 9():5323-35. PubMed ID: 26451087
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Upregulation and activation of PKC alpha by ErbB2 through Src promotes breast cancer cell invasion that can be blocked by combined treatment with PKC alpha and Src inhibitors.
    Tan M; Li P; Sun M; Yin G; Yu D
    Oncogene; 2006 Jun; 25(23):3286-95. PubMed ID: 16407820
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rho and Rho kinase are involved in parathyroid hormone-stimulated protein kinase C alpha translocation and IL-6 promoter activity in osteoblastic cells.
    Radeff JM; Nagy Z; Stern PH
    J Bone Miner Res; 2004 Nov; 19(11):1882-91. PubMed ID: 15476589
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lapatinib alters the malignant phenotype of osteosarcoma cells via downregulation of the activity of the HER2-PI3K/AKT-FASN axis in vitro.
    Long XH; Zhang GM; Peng AF; Luo QF; Zhang L; Wen HC; Zhou RP; Gao S; Zhou Y; Liu ZL
    Oncol Rep; 2014 Jan; 31(1):328-34. PubMed ID: 24172910
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Protein kinase C alpha trigger Ras and Raf-independent MEK/ERK activation for TPA-induced growth inhibition of human hepatoma cell HepG2.
    Wen-Sheng W
    Cancer Lett; 2006 Jul; 239(1):27-35. PubMed ID: 16169661
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Efficacy of the third-generation bisphosphonate risedronate alone and in combination with anticancer drugs against osteosarcoma cell lines.
    Murayama T; Kawasoe Y; Yamashita Y; Ueno Y; Minami S; Yokouchi M; Komiya S
    Anticancer Res; 2008; 28(4B):2147-54. PubMed ID: 18751388
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inhibition of the growth of glioblastomas by CGP 41251, an inhibitor of protein kinase C, and by a phorbol ester tumor promoter.
    Begemann M; Kashimawo SA; Choi YA; Kim S; Christiansen KM; Duigou G; Mueller M; Schieren I; Ghosh S; Fabbro D; Lampen NM; Heitjan DF; Schiff PB; Bruce JN; Weinstein IB
    Clin Cancer Res; 1996 Jun; 2(6):1017-30. PubMed ID: 9816263
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.